IFNA1 and depressive symptom measurement: During IFN-α therapy, the increased levels of serum KYN and 3-HK tended to be higher in depression (+) patients than in depression (−) patients and there were significant increases of 3-HK level in depression (+) patients than in depression (−) patients at 2 weeks after the onset of therapy (Fig. 1 and Table 2).